Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y

Core Insights - Repligen Corporation (RGEN) reported fourth-quarter 2025 adjusted earnings per share of 49 cents, exceeding both the Zacks Consensus Estimate and the previous year's adjusted earnings of 44 cents per share [1] - Total revenues for the fourth quarter reached $198 million, reflecting an 18% year-over-year increase, and surpassing the Zacks Consensus Estimate of $192 million [1][6] - The company achieved 14% organic revenue growth in the fourth quarter, excluding acquisition and COVID-related revenues [5][6] Revenue Breakdown - Product revenues amounted to $197.7 million, up 18.1% from the previous year, while royalty and other revenues were $0.2 million, increasing by 20% year over year [4] - Revenues from consumables grew over 20%, and biopharma revenues increased by 20% year-over-year, driven by growth in both pharma and emerging biotech sectors [6] - Proteins and Process Analytics revenues grew more than 30%, while Chromatography revenues increased by over 25% year-over-year [7] Financial Performance - Adjusted gross margin was reported at 52.4%, an increase of 170 basis points year-over-year [8] - Adjusted operating income for the quarter was $30 million, reflecting a 20% increase from the previous year [8] - As of December 31, 2025, the company had cash and cash equivalents of $768 million, up from $749 million as of September 30, 2025 [9] Full-Year Results and Guidance - For the full year 2025, Repligen generated revenues of $738.3 million, representing approximately 16% growth year-over-year, with adjusted earnings of $1.71 per share, up from $1.58 per share in the prior year [10] - The company expects total revenues for 2026 to be in the range of $810-$840 million, with adjusted EPS anticipated between $1.93 and $2.01 [11] - Adjusted gross margin for 2026 is projected to be between 53.6% and 54.1%, with adjusted operating income expected to range from $122 million to $130 million [11]